Sort   by:  
 Page size 
TranscriptomicsGene expression analysis of GzmB-/- hematopoietic stem cells (HSC).
This study aimed to compare the expression profile of GzmB deficient HSCs and their WT counterparts in order to understand their phenotype in bone marrow in vivo reconstitution assays. GzmB-/- HSC mRNA expression was compared to WT counterparts. Samples of 3 biological replicates (pool of 3 mice pe...
ORGANISM(S): Mus musculus 
2014-04-11 | E-GEOD-56574 | biostudies-arrayexpress
TranscriptomicsRNA-seq of 7 breast PDX models treated with Fulvestrant and AZD9833/camizestrant and collected at multiple timepoints
Oral selective estrogen receptor degraders (SERDs) could become the backbone endocrine therapy (ET) for estrogen receptor-positive (ER+) breast cancer, as they achieve greater inhibition of ER-driven cancers than current ETs and overcome key resistance mechanisms. This dataset was aimed at exploring...
ORGANISM(S): Homo sapiens 
2023-09-11 | E-MTAB-13139 | biostudies-arrayexpress
TranscriptomicsRNA-seq of human breast cancer cell lines MCF7 and CAMA1 treated with Fulvestrant, AZD9496 and AZD9833/camizestrant, with and without estradiol
Oral selective estrogen receptor degraders (SERDs) could become the backbone endocrine therapy (ET) for estrogen receptor-positive (ER+) breast cancer, as they achieve greater inhibition of ER-driven cancers than current ETs and overcome key resistance mechanisms. This dataset was aimed at exploring...
ORGANISM(S): Homo sapiens 
2023-09-11 | E-MTAB-13113 | biostudies-arrayexpress
TranscriptomicsMouse_embryoid Body_Retinoic acid treatment
S6K1 Knockout mice has a lean phenotype and resitant to a High Fat Diet-induced obesity (Um S.H., Nature, 2004). Adipocyte differentiation consists of two step, first, commitment from stem cell to adipocyte progenitors and second, terminal differentiation from adipocyte progenitors to mature adipocy...
ORGANISM(S): Mus musculus 
2010-05-14 | E-GEOD-20349 | biostudies-arrayexpress
TranscriptomicsmTOR inhibitors synergistically induce regression, reversal of gene expression and autophagy in hepatocellular carcinoma
The mTOR-allosteric inhibitor, RAD001, in combination with a PI3K/mTOR ATP-site competitive inhibitor, BEZ235, causes gene reprogramming, autophagy and tumor regression, in a mouse model approximating human HCC with poor prognosis, leading to an investigator Phase 1B-2 clinical trial. Comparative st...
ORGANISM(S): Mus musculus 
2012-07-11 | E-GEOD-37129 | biostudies-arrayexpress
TranscriptomicsRNAseq of tumor samples from CT26 syngeneic mouse treated with a PD-L1 and CTLA-4 immunotherapy combination
The ability to modulate immune-inhibitory pathways using checkpoint blockade antibodies such as PD-1, PD-L1, and CTLA-4 represents a significant breakthrough in cancer therapy in recent years. This has driven interest in identifying small-molecule-immunotherapy combinations to increase the proportio...
ORGANISM(S): Mus musculus 
2020-04-16 | E-MTAB-7777 | biostudies-arrayexpress
TranscriptomicsRNAseq of tumor samples from CT26 syngeneic mouse treated with a PI3Ka/d inhibitor (AZD8835)
PI3K inhibitors with differential selectivity to distinct PI3K isoforms have been tested extensively in clinical trials, largely to target tumor epithelial cells. PI3K signaling also regulates the immune system and inhibition of PI3Kdelta modulate the tumor immune microenvironment of pre-clinical mo...
ORGANISM(S): Mus musculus 
2019-01-08 | E-MTAB-7386 | biostudies-arrayexpress
TranscriptomicsRNAseq profiling of tumor, tumor-draining-lymph nodes, blood and tumor-associated macrophages of MC38 mice treated with the PI3Kg inhibitor AZD3458 and a combination of AZD3458 and anti-PD-1
RNAseq profiling of AZD3458 monotherapy and combination treatment with anti-PD-1 of whole tumors, isolated tumor macrophages (Mac) (CD45+CD11b+F4/80+), whole blood (PB) and tumor draining lymph nodes (TDLN) were assessed to elucidate further mechanisms leading to enhanced combination activity.
ORGANISM(S): Mus musculus 
2021-02-28 | E-MTAB-10057 | biostudies-arrayexpress
TranscriptomicsRNA-seq of human breast cancer cell lines MCF7 and T74D naive and resistant to palbociclib treated with capivasertib, fulvestrant and combination
T47D and MCF7 cell lines were treated with long-term (continuous) palbociclib to induce 4 resistant cell-lines (T47D RB-, T47D CDK6H, MCF7 RB- and MCF7 PacqR). Each cell line (both parental and resistant) were then treated with DMSO (control), capivasertib monotherapy, fulvestrant monotherapy and ca...
ORGANISM(S): Homo sapiens 
2023-08-14 | E-MTAB-13262 | biostudies-arrayexpress
Sort   by:  
 Page size